STOCK TITAN

Heron Therapeutics (HRTX) CFO reports RSU vesting and share withholding

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Heron Therapeutics EVP and Chief Financial Officer Ira Duarte reported equity compensation activity involving restricted stock units that settled into common stock on July 30 and 31, 2026. In total, 25,229 RSUs converted into an equal number of common shares, while 7,176 shares were withheld at $0.50 per share in transactions reported under code F for payment of exercise price or tax liability. The RSUs include a 216,562-unit grant awarded on January 30, 2026 that vests in 16 equal quarterly installments beginning one quarter after the grant date, as well as an earlier grant from January 31, 2025 with the same 16-installment vesting structure.

Positive

  • None.

Negative

  • None.
Insider Duarte Ira
Role EVP, Chief Financial Officer
Type Security Shares Price Value
Exercise Restricted Stock Units F3 11,694 $0.00 $0.00
Exercise Common Stock F1 11,694 -- --
Exercise Price or Tax Liability Common Stock 3,326 $0.50 $2K
Exercise Restricted Stock Units F2 13,535 $0.00 $0.00
Exercise Common Stock F1 13,535 -- --
Exercise Price or Tax Liability Common Stock 3,850 $0.50 $2K
Holdings After Transaction: Restricted Stock Units — 306,436 shares (Direct); Common Stock — 281,899 shares (Direct)
Footnotes (3)
  1. F1. Each restricted stock unit represents a contingent right to receive one share of common stock.
  2. F2. On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.
  3. F3. The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).
RSUs converted 25,229 shares Total restricted stock units exercised or converted into common stock on July 30–31, 2026
Shares withheld 7,176 shares Common shares withheld in code F transactions for exercise price or tax liability
Withholding price $0.5000 per share Price applied to common shares withheld under code F transactions
RSU grant size 216,562 RSUs Restricted stock units granted to Ira Duarte on January 30, 2026
Vesting installments 16 installments RSU grants vest in 16 equal (quarterly) installments beginning one quarter after grant
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
Payment of exercise price or tax liability by delivering or withholding securities financial
"transaction_code_description: Payment of exercise price or tax liability by delivering or withholding securities"
time-based vesting schedule financial
"granted 216,562 RSUs which vest upon the following time-based vesting schedule"
Date of Grant financial
"On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider activity did Heron Therapeutics (HRTX) report for CFO Ira Duarte?

Heron Therapeutics reported that CFO Ira Duarte converted 25,229 restricted stock units into common shares on July 30–31, 2026. In connection with these settlements, 7,176 shares were withheld at $0.50 per share to satisfy obligations reported under code F.

How many restricted stock units did HRTX CFO Duarte have in the January 30, 2026 grant?

On January 30, 2026, CFO Ira Duarte was granted 216,562 restricted stock units. According to the award terms, these RSUs vest in 16 equal quarterly installments, starting one quarter after the grant date, creating periodic conversions into common stock.

What does the code F transaction mean in the HRTX Form 4 for Ira Duarte?

Code F indicates shares used for payment of exercise price or tax liability by delivering or withholding securities. Duarte had 7,176 common shares withheld at $0.50 per share in such transactions related to the RSU settlements on July 30 and 31, 2026.

Were Ira Duarte’s HRTX transactions open‑market buys or sells?

The reported transactions involve RSU vesting and settlement, plus share withholding under code F, rather than open‑market purchases or sales. RSUs converted into 25,229 common shares, with 7,176 of those shares withheld to cover obligations tied to the awards.

What vesting schedule applies to Ira Duarte’s HRTX restricted stock units?

Duarte’s RSU grants described here vest in 16 equal installments, beginning one quarter after their respective grant dates (including a 216,562-unit grant dated January 30, 2026). Each vested unit delivers one share of Heron Therapeutics common stock upon settlement.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Duarte Ira

(Last)(First)(Middle)
25 FENTON MAIN STREET
SUITE 300

(Street)
CARY NORTH CAROLINA 27511

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
HERON THERAPEUTICS, INC. /DE/ [ HRTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/30/2026M13,535A(1)277,381D
Common Stock07/30/2026F3,850D$0.5273,531D
Common Stock07/31/2026M11,694A(1)285,225D
Common Stock07/31/2026F3,326D$0.5281,899D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$007/30/2026M13,535 (2) (2)Common Stock13,535$0189,492D
Restricted Stock Units$007/31/2026M11,694 (3) (3)Common Stock11,694$0116,944D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of common stock.
2. On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 216,562 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.
3. The restricted stock units vest in 16 equal installments beginning one quarter after the date of grant (January 31, 2025).
/s/Kathryn Lester Attorney-in-fact for Ira Duarte08/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)